Molecular characterization of AML with RUNX1-RUNX1T1 at diagnosis and relapse reveals net loss of co-mutations

AML with RUNX1-RUNX1T1 fusion is a WHO entity with a favorable outcome following intensive chemotherapy. The absence of RUNX1-RUNX1T1 transcripts in remission defines complete molecular response and correlates with a superior survival. However, a significant proportion of patients still relapses and...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Hemasphere
Hlavní autoři: Höllein, Alexander, Nadarajah, Niroshan, Meggendorfer, Manja, Jeromin, Sabine, Kern, Wolfgang, Haferlach, Claudia, Haferlach, Torsten
Médium: Artigo
Jazyk:Inglês
Vydáno: Wolters Kluwer Health 2019
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6745937/
https://ncbi.nlm.nih.gov/pubmed/31723813
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/HS9.0000000000000178
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky